Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200-Day Moving Average – Here’s What Happened

Champions Oncology, Inc. (NASDAQ:CSBR)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.48 and traded as low as $5.85. Champions Oncology shares last traded at $6.04, with a volume of 5,373 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Champions Oncology from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, March 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Champions Oncology Price Performance

The firm has a market cap of $81.40 million, a PE ratio of -36.63 and a beta of 0.40. The business’s 50 day moving average price is $5.96 and its 200 day moving average price is $6.47.

Institutional Trading of Champions Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of Champions Oncology during the second quarter worth about $103,000. Essex Investment Management Co. LLC acquired a new position in Champions Oncology during the fourth quarter worth about $126,000. Jane Street Group LLC acquired a new position in Champions Oncology during the first quarter worth about $200,000. Goldman Sachs Group Inc. acquired a new position in Champions Oncology during the first quarter worth about $201,000. Finally, Acadian Asset Management LLC boosted its position in Champions Oncology by 28.7% during the first quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 8,814 shares during the last quarter. Hedge funds and other institutional investors own 41.30% of the company’s stock.

Champions Oncology Company Profile

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.